Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)
Status:
Completed
Trial end date:
2015-08-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of MK-1075, and to
determine the ability of MK-1075 to reduce HCV viral load, following administration of a
single dose in HCV-infected participants.